Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KHN702 in Chinese Healthy Volunteers
NCT07044960Phase 1Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of KHN702 in acute pain and postoperative pain (2 arms), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Incidence and severity of adverse events at Day 10. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
KHN702
03
Conditions
acute painpostoperative pain
Beyond the preview
Go deeper on NCT07044960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044960.